Waltham, United States
Ensem Therapeutics, founded in 2021 and headquartered in the United States, is making significant strides in the field of precision medicine with its proprietary Kinetic Ensemble™ Platform. This platform integrates cutting-edge computational techniques and AI, with advanced experimental methods to facilitate the discovery of small molecule medicines primarily targeting oncology. The technology has the potential to broaden its scope to genetic disorders and other challenging diseases.
The company recently secured a $10.00M Series A investment on 01 October 2023, backed by prominent investors, including Legend Star, Boquan Capital, and MegaRobo. This funding round signifies the confidence of investors in Ensem's ability to effectively tackle high-value, hard-to-drug targets, leveraging its innovative approach to drug design.
